Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicenter, randomized, double-blinded, placebo-controlled trial

Puntos clave

• This research investigates whether deucravacitinib effectively promotes hair regrowth in alopecia areata patients.
• Conducted as a multicenter, randomized, double-blinded, placebo-controlled trial
• Evaluated efficacy endpoints related to hair regrowth
• Assessed safety profile relative to known outcomes for TYK2 inhibitor
• Trial did not meet efficacy endpoints for hair regrowth
• Deucravacitinib's safety profile aligns with previous data for TYK2 inhibitors